Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report.
Drugs R D 5(6):315-26 (2004) PMID 15563234
To evaluate the response rates, survival and toxicity of treatment with antineoplaston A10 and AS2-1 (ANP) in the first 12 children enrolled in our studies diagnosed with incurable recurrent and progressive multicentric glioma.
Version: za2963e q8za1 q8zb1 q8zcc q8zd7 q8ze4 q8zfb q8zg9